Tag Archives: Warren Woessner

Eurand v. Mylan –A “School Of Obviousness”

Posted on April 20, 2012 by Warren Woessner

When I read the April 16th decision (App. No. 2011-1399, -1409 (Fed. Cir. April 16, 2012)) (a copy is available at the end of this post) in which a Fed. Cir. panel of Newman, O’Malley and Reyna reversed a district … Continue reading →

Major Changes to IP Law in Australia Enacted

Posted on April 19, 2012 by Warren Woessner

This guest post by Tom Gumley, PhD, a partner in the well-known Freehills Patent and Trademark firm provides a lengthy guide to the changes wrought by Australia’s new patent law, that was enacted on April 15, 2012. The law brings … Continue reading →

Posted in Int'l Practice and Policy | Tagged Australia, Freehills Patent, intellectual property, ip, IP law tools, Patent Law, patents, Tom Gumley, Warren Woessner | Leave a comment

Supreme Court Reverses In Caraco Appeal

Posted on April 17, 2012 by Warren Woessner

Today, in Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk, in an opinion authored by Justice Kagan (a copy can be found at the end of this post), the Court reversed the Fed. Cir.’s divided 2010 decision that an ANDA filer … Continue reading →

Posted in Hatch-Waxman | Tagged ANDA, biotechnology law, biotechnology news, caraco, Federal Circuit, Hatch-Waxman, intellectual property, ip, IP law tools, Justice Kagen, Patent Law, patents, Pharmaceutical law, Supreme Court, Warren Woessner | 1 Comment

Aventis v. Hospira – How to Meet the Therasense Standards

Posted on April 10, 2012 by Warren Woessner

On April 9, 2012, The Fed. Cir. affirmed a holding by the district court that rendered two (then) Sanofi add-on patents on infusion vehicles for docetaxel unenforceable due to inequitable conduct. The inventors, particularly inventor/project manager Fabre, were found to have … Continue reading →